Is PLX or PMN more undervalued in 2026?

CirclFi compares Protalix BioTherapeutics, Inc. (PLX) and ProMIS Neurosciences Inc. (PMN) using 13 institutional-grade valuation models. PLX has a Quality of Company score of 7.6/10 while PMN scores 4.2/10.

Which is a better buy — PLX or PMN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PLX and PMN valuations compare?

PLX at $2.10 and PMN at $10.87 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PLX vs PMN Valuation Comparison 2026 — Intrinsic Value Analysis

PLX

Biotechnology

Protalix BioTherapeutics, Inc.

Quality

7.6

out of 10

Value Trap

SAFE

Price

$2.10

Last close

Models

12/13

Active

PMN

Biotechnology

ProMIS Neurosciences Inc.

Quality

4.2

out of 10

Value Trap

LOW

Price

$10.87

Last close

Models

6/13

Active

Model-by-Model Comparison

Model	Type	PLX Fair Value	PLX Upside	PMN Fair Value	PMN Upside
Bayesian DCF	Intrinsic	$1.66	-20.9%	$6.79	-37.5%
Earnings Power Value	Intrinsic	$3.20	+52.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.50	-76.1%	$10.85	-0.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PLX vs PMN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PLX vs PMN — Which Stock Is More Undervalued?

PLX scores higher with a 7.6/10 quality rating vs PMN's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Protalix BioTherapeutics, Inc. (PLX) and ProMIS Neurosciences Inc. (PMN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PLX currently trades at $2.10 with a QOC of 7.6/10, while PMN trades at $10.87 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).